|
1
|
Komatsu H: Hepatitis B virus: Where do we
stand and what is the next step for eradication? World J
Gastroenterol:. 20:8998–9016. 2014.PubMed/NCBI
|
|
2
|
Xu DZ, Yan YP, Choi BC, Xu JQ, Men K,
Zhang JX, Liu ZH and Wang FS: Risk factors and mechanism of
transplacental transmission of hepatitis B virus: A case-control
study. J Med Virol. 67:20–26. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Werle-Lapostolle B, Bowden S, Locarnini S,
Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, WE
VI Delaney, et al: Persistence of cccDNA during the natural history
of chronic hepatitis B and decline during adefovir dipivoxil
therapy. Gastroenterology. 126:1750–1758. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hsu PD, Lander ES and Zhang F: Development
and applications of CRISPR-Cas9 for genome engineering. Cell.
157:1262–1278. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Barrangou R and Marraffini LA: CRISPR-Cas
systems: Prokaryotes upgrade to adaptive immunity. Mol Cell.
54:234–244. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cong L, Ran FA, Cox D, Lin S, Barretto R,
Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA and Zhang F:
Multiplex genome engineering using CRISPR/Cas systems. Science.
339:819–823. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang T, Wei JJ, Sabatini DM and Lander ES:
Genetic screens in human cells using the CRISPR-Cas9 system.
Science. 343:80–84. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang H, Wang H, Shivalila CS, Cheng AW,
Shi L and Jaenisch R: One-step generation of mice carrying reporter
and conditional alleles by CRISPR/Cas-mediated genome engineering.
Cell. 154:1370–1379. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gratz SJ, Cummings AM, Nguyen JN, Hamm DC,
Donohue LK, Harrison MM, Wildonger J and O'Connor-Giles KM: Genome
engineering of Drosophila with the CRISPR RNA-guided Cas9 nuclease.
Genetics. 194:1029–1035. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chang N, Sun C, Gao L, Zhu D, Xu X, Zhu X,
Xiong JW and Xi JJ: Genome editing with RNA-guided Cas9 nuclease in
zebrafish embryos. Cell Res. 23:465–472. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hu Z, Yu L, Zhu D, Ding W, Wang X, Zhang
C, Wang L, Jiang X, Shen H, He D, et al: Disruption of HPV16-E7 by
CRISPR/Cas system induces apoptosis and growth inhibition in HPV16
positive human cervical cancer cells. Biomed Res Int.
2014:6128232014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu W, Kaminski R, Yang F, Zhang Y,
Cosentino L, Li F, Luo B, Alvarez-Carbonell D, Garcia-Mesa Y, Karn
J, et al: RNA-directed gene editing specifically eradicates latent
and prevents new HIV-1 infection. Proc Natl Acad Sci USA.
111:11461–11466. 2014; View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang J and Quake SR: RNA-guided
endonuclease provides a therapeutic strategy to cure latent
herpesviridae infection. Proc Natl Acad Sci USA. 111:13157–13162.
2014; View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dong C, Qu L, Wang H, Wei L, Dong Y and
Xiong S: Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease
efficiently inhibits viral replication. Antiviral Res. 118:110–117.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Seeger C and Sohn JA: Targeting hepatitis
B virus with CRISPR/Cas9. Mol Ther Nucleic Acids. 3:e2162014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhen S, Hua L, Liu YH, Gao LC, Fu J, Wan
DY, Dong LH, Song HF and Gao X: Harnessing the clustered regularly
interspaced short palindromic repeat (CRISPR)/CRISPR-associated
Cas9 system to disrupt the hepatitis B virus. Gene Ther.
22:404–412. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jilbert AR, Botten JA, Miller DS, Bertram
EM, Hall PM, Kotlarski J and Burrell CJ: Characterization of age-
and dose-related outcomes of duck hepatitis B virus infection.
Virology. 244:273–282. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang YY, Theele DP and Summers J:
Age-related differences in amplification of covalently closed
circular DNA at early times after duck hepatitis B virus infection
of ducks. J Virol. 79:9896–9903. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tuttleman JS, Pugh JC and Summers JW: In
vitro experimental infection of primary duck hepatocyte cultures
with duck hepatitis B virus. J Virol. 58:17–25. 1986.PubMed/NCBI
|
|
20
|
Marion PL, Salazar FH, Winters MA and
Colonno RJ: Potent efficacy of entecavir (BMS-200475) in a duck
model of hepatitis B virus replication. Antimicrob Agents
Chemother. 46:82–88. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Miller JC, Holmes MC, Wang J, Guschin DY,
Lee YL, Rupniewski I, Beausejour CM, Waite AJ, Wang NS, Kim KA, et
al: An improved zinc-finger nuclease architecture for highly
specific genome editing. Nat Biotechnol. 25:778–785. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miller JC, Tan S, Qiao G, Barlow KA, Wang
J, Xia DF, Meng X, Paschon DE, Leung E, Hinkley SJ, et al: A TALE
nuclease architecture for efficient genome editing. Nat Biotechnol.
29:143–148. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Barrangou R: RNA-mediated programmable DNA
cleavage. Nat Biotechnol. 30:836–838. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim Y, Kweon J, Kim A, Chon JK, Yoo JY,
Kim HJ, Kim S, Lee C, Jeong E, Chung E, et al: A library of TAL
effector nucleases spanning the human genome. Nat Biotechnol.
31:251–258. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Grissa I, Vergnaud G and Pourcel C: The
CRISPRdb database and tools to display CRISPRs and to generate
dictionaries of spacers and repeats. BMC Bioinformatics. 8:1722007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ramanan V, Shlomai A, Cox DB, Schwartz RE,
Michailidis E, Bhatta A, Scott DA, Zhang F, Rice CM, Bhatia SN, et
al: CRISPR/Cas9 cleavage of viral DNA efficiently suppresses
hepatitis B virus. Sci Rep. 5:108332015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ebina H, Misawa N, Kanemura Y and Koyanagi
Y: Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1
provirus. Sci Rep. 3:25102013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kennedy EM, Kornepati AV and Cullen BR:
Targeting hepatitis B virus cccDNA using CRISPR/Cas9. Antiviral
Res. 123:188–192. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lin SR, Yang HC, Kuo YT, Liu CJ, Yang TY,
Sung KC, Lin YY, Wang HY, Wang CC, Shen YC, et al: The CRISPR/Cas9
system facilitates clearance of the intrahepatic HBV templates In
Vivo. Mol Ther Nucleic Acids. 3:e1862014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kennedy EM, Bassit LC, Mueller H,
Kornepati AV, Bogerd HP, Nie T, Chatterjee P, Javanbakht H,
Schinazi RF, Cullen BR, et al: Suppression of hepatitis B virus DNA
accumulation in chronically infected cells using a bacterial
CRISPR/Cas RNA-guided DNA endonuclease. Virology. 476:196–205.
2015. View Article : Google Scholar : PubMed/NCBI
|
